X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the termination, Infinity has continued to prepare for the initiation of a planned global Phase 2 clinical trial evaluating IPI-549 (eganelisib) in head and neck squamous cell carcinoma.
Lead Product(s): Eganelisib,Nivolumab
Therapeutic Area: Oncology Product Name: IPI-549
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: MEI Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Termination July 24, 2023
Details:
IPI-549 (eganelisib) is a first-in-class, oral, once-daily, immuno-oncology candidate that selectively inhibits phosphoinositide-3-kinase gamma, which is investigated in Combination with Pembrolizumab in Patients with Squamous Cell Cancer of the Head and Neck (SCCHN).
Lead Product(s): Eganelisib,Pembrolizumab
Therapeutic Area: Oncology Product Name: IPI-549
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: MEI Pharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 10, 2023
Details:
The Combination will create a company with a diverse product development pipeline led by a planned new global Phase 2 clinical trial evaluating IPI-549 (eganelisib) in head and neck squamous cell carcinoma (HNSCC)
Lead Product(s): Eganelisib,Pembrolizumab
Therapeutic Area: Oncology Product Name: IPI-549
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: MEI Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger February 23, 2023
Details:
IPI-54 (Eganelisb) in combination therapy has demonstrated positive resutls total tumor volume reduction is 92.8% and 85.2%, and disease control rates is 92.8% and 81.4%, in PD-L1 frontline TNBC patients.
Lead Product(s): Eganelisib,Atezolizumab,Paclitaxel
Therapeutic Area: Oncology Product Name: IPI-549
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 05, 2022
Details:
IPI-549 (eganelisib ), a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic addresses a fundamental biologic mechanism of immune suppression in cancer in multiple clinical studies.
Lead Product(s): Eganelisib,Atezolizumab,Paclitaxel
Therapeutic Area: Oncology Product Name: IPI-549
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 10, 2021
Details:
IPI-549 (eganelisib) immuno-oncology macrophage reprogramming therapeutic that selectively inhibits phosphoinositide-3-kinase gamma used as a frontline regimentriple negative breast cancer.
Lead Product(s): Eganelisib,Atezolizumab,Paclitaxel
Therapeutic Area: Oncology Product Name: IPI-549
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 06, 2021
Details:
At the one-year landmark, 59% of patients in the ITT population receiving the eganelisib plus nivolumab combination remained alive, compared to 32% in the nivolumab control arm.
Lead Product(s): Eganelisib,Atezolizumab,Paclitaxel
Therapeutic Area: Oncology Product Name: IPI-549
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 27, 2021
Details:
MARIO-3 is a Phase 2 triplet combination study evaluating the addition of eganelisib to the approved standard of care combination of Tecentriq® and Abraxane® in the front-line setting in TNBC.
Lead Product(s): Eganelisib,Atezolizumab,Paclitaxel
Therapeutic Area: Oncology Product Name: IPI-549
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 20, 2021
Details:
In collaboration with Arcus Biosciences, Infinity is evaluating a checkpoint inhibitor-free, novel combination regimen of eganelisib plus etrumadenant (AB928, a dual adenosine receptor antagonist) plus Doxil® in advanced TNBC patients.
Lead Product(s): Eganelisib,Nivolumab
Therapeutic Area: Oncology Product Name: IPI-549
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Arcus Biosciences
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 14, 2021
Details:
The Phase 1b clinical trial is a global multi-center, open-label trial of CERC-007 that will enroll around 12 subjects with active adult onset Still’s disease with a primal goal of the study will be to determine the safety and tolerability of CERC-007 in AOSD patients.
Lead Product(s): Eganelisib,Etrumadenant
Therapeutic Area: Oncology Product Name: IPI-549
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Arcus Biosciences
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 05, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
